PRIME-CKD at ASN Kidney Week 2025

PRIME-CKD is excited to participate in ASN Kidney Week 2025 in Houston!
Many consortium members will actively contribute to the program through oral and poster presentations. Don’t miss the latest updates on PRIME-CKD’s progress.

November 6: First Results from the UVALID Study
November 6 marks a major milestone with the presentation of the first results from the multicenter UVALID study—a true team effort. This study examined the biomarkers epidermal growth factor (EGF) and clusterin (CLU) for their variability and stability during long-term frozen storage. These findings provide a strong foundation for the broader goals of the PRIME-CKD project.

Learn more during the poster session Intra-Individual Variability of Urinary Epidermal Growth Factor and Clusterin, and Effect of Frozen Storage on Stability: Results from UVALID.
Fantastic work from our researchers from Hamburg (DE), Ann Arbor (MI, USA), Groningen (NL), Copenhagen (DK), Valencia (ES), and Bologna (IT)!

Also on November 6: Presentations on biomarkers and CKD risk stratification
Be sure to attend both the poster and oral presentations by Erik Moedt titled Predictive Value of Established and Novel Biomarkers for Kidney Outcomes in CKD: A Comparative and Validation Study.
Erik will demonstrate how a combined biomarker approach enhances CKD risk stratification compared to individual biomarkers. This highlights the importance of an integrated strategy to better assess CKD progression risk.

November 8: New Insights from DAPA-CKD
On November 8, André de la Rambelje will present the poster Association of Circulating Protein Levels With Kidney Outcome in Patients With Chronic Kidney Disease and the Effect of Dapagliflozin: New Insights from DAPA-CKD.
Using plasma proteomics, this study explores how the SGLT2 inhibitor dapagliflozin affects CKD progression. André reveals that dapagliflozin targets key pathways involved in inflammation and fibrosis—critical processes in CKD development.

Meet Us in Houston
Many PRIME-CKD researchers will be attending the ASN Kidney Week in Houston and are eager to engage in discussions about personalized medicine in CKD. Don’t miss the opportunity to connect!